Semax (natively labeled Семакс) is a Russian pharmaceutical neuropeptide developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period. While commonly prescribed in Russia, Ukraine, and other CIS nations for a wide range of conditions including stroke/ischemic brain injury, Alzheimer's, depression, generalized anxiety, peptic ulcer disease, and weakened immune system, it has gained limited recognition elsewhere as a nootropic due to its mildly stimulating and anxiolytic effects, neuroprotective properties, and limited side effect profile.
Semax molecular structure diagram from the DrugsPRO substance library.
Classification
No data available for this section yet.
Effects
No data available for this section yet.
Routes of Administration
Insufflated
Dosage
Bioavailability: 1200 mg
Threshold: 50 ug
Light: 50 - 100 µg
Common: 100 - 500 µg
Strong: 500 - 1200 µg
Heavy: 1.2 mg
Duration
No data available for this section yet.
Subcutaneous
Dosage
Bioavailability: ~99%
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Semax - DrugsPRO substance guide
Semax: Semax (natively labeled Семакс) is a Russian pharmaceutical neuropeptide developed in the 1980s and approved for clinical use in 1996 after a 14-year-long testing period. While commonly prescribed in Russia, Ukraine, and other CIS nations for a wide range of conditions including stroke/ischem
